A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia

Sumitomo Pharma America, Inc.678 enrolled

Overview

To evaluate the antidepressant effect of adjunctive treatment with Eszopiclone in subjects receiving venlafaxine for the treatment of Major Depressive Disorder (MDD).

This is a double-blind, randomized, placebo-controlled, parallel-group study. The study consists of two groups of subjects with Major Depressive Disorder randomized to treatment with either eszopiclone 3 mg or placebo nightly at bedtime for 31 weeks beginning the night of Visit 2. In addition, all subjects will receive open-label treatment with venlafaxine. Safety and efficacy will be evaluated using clinical observations as well as physician and subject administered ratings scales. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

678

Conditions

Major Depressive Disorder Insomnia

Interventions

EszopicloneDRUG

Eszopiclone 3 mg

PlaceboDRUG

Placebo

VenlafaxineDRUG

Venlafaxine 75 mcg Weeks 1, 2, 29, and 30 Venlafaxine 150 mcg Weeks 3 through 28

Eligibility

Sex: ALLMin age: 18 YearsMax age: 64 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects must be male or female between the ages of 18 and 64, inclusive, at the time of signing consent. * Subjects must have a primary diagnosis of Major Depressive Disorder (MDD) by DSM-IV criteria (296.XX) as determined by the Mini International Neuropsychiatric Interview (M.I.N.I.). * MDD must be the condition that was chiefly responsible for motivating the subject to seek treatment. * Subjects must have a 17-item Hamilton Depression Scale (HAM-D-17) total score of \> 22 at the screening visit. Exclusion Criteria: * Subjects who have a HAM-D-17 total score \< 18 at Visit 2 will be discontinued from the study. * All subjects who do not meet DSM-IV criteria (307.42) for Insomnia related to a Major Depressive Disorder. * Subjects with less than a total sleep time \< 6.5 hours at least three times per week over the past month.

Locations (69)

Outcomes

Primary Outcomes

The primary endpoint is the change from baseline in HAM-D-17 total score at Week 8.

Time frame: Week 8

Secondary Outcomes

The key secondary endpoint is the change from baseline in the mean subjective Total Sleep Time (TST) during Week 1.

Time frame: Week 1

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Salzburg, Austria

Unnamed facility

Vienna, Austria

Unnamed facility

Vienna, Austria

Unnamed facility

Split, Croatia

Unnamed facility

Zagreb, Croatia

Unnamed facility

Zagreb, Croatia

Unnamed facility

Arcachon, France

Unnamed facility

Caen, France

Unnamed facility

Élancourt, France

Unnamed facility

Le Pecq, France

...and 59 more locations